AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25531677
Drug: Control (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (oral glucose-lowering drugs excluding TZD)
Trial: 21327593
Drug: Repeated pulse
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated pulse therapy of methylprednisolone (1 g for 3 days) and cyclophosphamide (15 mg/kg per day for 2 days), followed by dexamethasone (5 mg every 6 hours) until PaO2 >80 mmHg or repeated 1 g MP for 3 days and 1 g CP for 1 day if PaO2 <60 mmHg
Trial: 21327593
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of cyclophosphamide (2 mg/kg per day) and dexamethasone (5 mg every 6 hours) for 14 days
Trial: 18685945
Drug: Landiolol 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.01 mg x kg(‐1) x min(‐1)
Trial: 18685945
Drug: Landiolol 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.02 mg x kg(‐1) x min(‐1)
Trial: 18685945
Drug: Landiolol 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.03 mg x kg(‐1) x min(‐1)
Trial: 18685945
Drug: Landiolol 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.04 mg x kg(‐1) x min(‐1)
Trial: 16573799
Drug: Lactulose (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (single dose)
Trial: 16573799
Drug: Lactulose (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (long-term administration)
Trial: 15339557
Drug: Transcatheter arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter arterial chemoembolization (TACE) and traditional Chinese medicine (TCM)
Trial: 10712318
Drug: Quinupristin/dalfopristin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinupristin/dalfopristin (7.5 mg/kg every 8 h)
Trial: 3895289
Drug: Iopamidol (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iopamidol (250 mg I/ml)
Trial: 3895289
Drug: Ioxithalamate (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioxithalamate (250 mg I/ml)
Trial: 22379745
Drug: Domperidone 10
RxNorm normalized name: domperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10 mg thrice daily plus omeprazole 20 mg twice daily
Trial: 18502357
Drug: alpha‐tocopherol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐tocopherol 300 mg orally 5 to 6 hours before surgery
Trial: 16005690
Drug: Clobazam (10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (10mg oral dose)
Trial: 10362210
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement (0.625 mg/day conjugated equine estrogens and 2.5 mg/day medroxyprogesterone acetate)
Trial: 10362210
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement plus lovastatin
Trial: 8964637
Drug: Kd 2
RxNorm normalized name: POLYQUATERNIUM-7 (70/30 ACRYLAMIDE/DADMAC; 1600 KD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kd 2 mEq/l (standard potassium removal)
Trial: 2167702
Drug: VAC (vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC (vincristine 1 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2)
Trial: 2167702
Drug: VACE (vincristine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VACE (vincristine 1 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2, etoposide 80 mg/m2 for 3 days)
Trial: 31182351
Drug: Nabilone (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (target 1–2 mg)
Trial: 29086911
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg phenylephrine
Trial: 29086911
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg ephedrine
Trial: 21818820
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) chemoradiotherapy
Trial: 8957977
Drug: Suxamethonium-Mivacurium combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium-Mivacurium combination
Trial: 8957977
Drug: Suxamethonium-Atracurium combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium-Atracurium combination
Trial: 6832465
Drug: Dithranol cream
RxNorm normalized name: Zithranol
DrugBank: Anthralin (DB11157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dithranol cream 0.25% and Dithranol stylus 0.2%
Trial: 30638644
Drug: Intranasal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sufentanil 0.7 μg/kg
Trial: 28413993
Drug: Sofosbuvir plus
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir plus oral weight based ribavirin for 24 weeks
Trial: 28413993
Drug: Sofosbuvir plus
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir plus oral weight based ribavirin and a 180 mcg Peg‐INF alpha 2a subcutaneous injection weekly for 12 weeks
Trial: 25994549
Drug: FLU-v (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLU-v (500 μg) and the adjuvant
Trial: 24491069
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment sequences
Trial: 19344076
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg daily for 12 weeks)
Trial: 17942579
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium intake (250 mmol [5.75 g] per day)
Trial: 17942579
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium intake (70 mmol [1.61 g] per day)
Trial: 8623970
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL bupivacaine 0.125% with 50 micrograms fentanyl followed by an infusion of 0.125% bupivacaine and 0.0002% fentanyl at 10 mL/h
Trial: 8623970
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL bupivacaine 0.125% followed by an infusion of 0.125% bupivacaine at 10 mL/h
Trial: 1611229
Drug: verlukast 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verlukast 8 mg
Trial: 1611229
Drug: verlukast 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verlukast 2 mg
Trial: 6689975
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (5000 units two hours before operation and then 12-hourly for seven days)
Trial: 6689975
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (same regimen as heparin)
Trial: 30317965
Drug: Immediate nonfunctional
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate nonfunctional loading of implants (20 implants)
Trial: 30317965
Drug: Conventional loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional loading protocol (19 implants)
Trial: 28076671
Drug: MOMCare (Brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOMCare (Brief Interpersonal Psychotherapy and/or antidepressants)
Trial: 19657182
Drug: Enhanced tinnitus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced tinnitus retraining therapy (TRT) including Jacobson's progressive muscle relaxation, physiotherapy, education via lectures, training of selective attention, and changes in appraisal, mental attitude, and behavior towards tinnitus.
Trial: 10788964
Drug: Mivacurium (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium (0.2 mg.kg‐1)
Trial: 10788964
Drug: Succinylcholine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1.5 mg.kg‐1)
Trial: 8794502
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate (FD) dosage reduction
Trial: 8794502
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no FD dosage reduction)
Trial: 1524625
Drug: Bronchoretard (theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchoretard (theophylline sustained-release preparation)
Trial: 1524625
Drug: Diffumal (theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diffumal (theophylline formulation of large consumption)
Trial: 2867023
Drug: Pirenzepine 100
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 100 mg nocte
Trial: 2867023
Drug: Pirenzepine 150
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 150 mg nocte
Trial: 24479642
Drug: Supervised multi-purpose
RxNorm normalized name: Corona Multi-Purpose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised multi-purpose exercise (MG)
Trial: 18634442
Drug: Eviprostat tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eviprostat tablet (6 tabs/day)
Trial: 18634442
Drug: EVI-F tablet
RxNorm normalized name: F-15599
DrugBank: F-15599 (DB16936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVI-F tablet (3 tabs/day)
Trial: 22229256
Drug: Subcutaneous gonadotropin-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous gonadotropin-releasing hormone agonist (goserelin, 3.6 mg)
Trial: 20452196
Drug: SFC250 (salmeterol/fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC250 (salmeterol/fluticasone propionate combination 50/250 microg bd)
Trial: 20452196
Drug: SFC500 (salmeterol/fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC500 (salmeterol/fluticasone propionate combination 50/500 microg bd)
Trial: 17592691
Drug: Supported discharge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supported discharge (home treatment)
Trial: 12003257
Drug: Plant sterol-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol-enriched spread (8.3% sterol content, 25 g/day)
Trial: 22799613
Drug: Triple-combination treatment
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-combination treatment (OM 40 mg/AML 10 mg/HCTZ 25 mg)
Trial: 22799613
Drug: Dual-combination treatments
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-combination treatments (OM 40 mg/AML 10 mg, OM 40 mg/HCTZ 25 mg, or AML 10 mg/HCTZ 25 mg)
Trial: 17278987
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (perindopril-based therapy, with possible addition of indapamide)
Trial: 12681371
Drug: 0.23 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.23 mg/kg ketamine hydrochloride followed by 0.5 mg/kg ketamine over 45 min
Trial: 1320287
Drug: nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nedocromil sodium (4 mg q.i.d.)
Trial: 6095322
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ACTH 4‐9 analog, ORG 2766
Trial: 24299513
Drug: Larval therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larval therapy dressing (BioFOAM)
Trial: 24299513
Drug: Hydrogel (Purilon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel (Purilon gel)
Trial: 22540269
Drug: Radiopaque ENG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiopaque ENG implant
Trial: 22540269
Drug: Non-radiopaque ENG
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-radiopaque ENG implant
Trial: 12066212
Drug: Oral doxifluridine
RxNorm normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral doxifluridine (5'‐DFUR)
Trial: 12066212
Drug: Oral 5‐fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5‐fluorouracil (5‐FU)
Trial: 9891531
Drug: 5‐FU injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU injections only (group B)
Trial: 2962837
Drug: Procaterol 0.1
RxNorm normalized name: procaterol 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol 0.1 mg
Trial: 12092746
Drug: Encapsulated enteric-coated
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated enteric-coated beads (400 mg)
Trial: 12092746
Drug: Buffered tablet
RxNorm normalized name: CVS Aspirin 325mg Buffered Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered tablet (400 mg)
Trial: 8697497
Drug: Mid-laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-laser treatment
Trial: 31432220
Drug: FREEWAY™ drug‐eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FREEWAY™ drug‐eluting balloon
Trial: 26038960
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) 300 mg formulation
Trial: 26038960
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) 100 mg formulation (reference product)
Trial: 9730427
Drug: Intravenous Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Tacrolimus
Trial: 9730427
Drug: Oral Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tacrolimus
Trial: 3292249
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate (loading dose 20 mg/kg, maintenance dose 10 mg/kg per day)
Trial: 29718460
Drug: Cigarettes with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes with 2.4-0.4 mg/g nicotine
Trial: 28538644
Drug: CD28 immunomodulator
RxNorm normalized name: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptor
DrugBank: Axicabtagene ciloleucel (DB13915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD28 immunomodulator (AB103) at 0.5 mg/kg, n = 15
Trial: 21809698
Drug: phenibut tablets
RxNorm normalized name: phenibut
DrugBank: Phenibut (DB13455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phenibut tablets
Trial: 16409440
Drug: Darifenacin 15
RxNorm normalized name: darifenacin 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin 15 mg once daily (qd)
Trial: 15700749
Drug: Hydroalcoholic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroalcoholic extract of C. curvisepala Lind. (3 times daily for more than 4 months)
Trial: 15700749
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 times daily for more than 4 months)
Trial: 1649718
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin treatment (36 units/kg intravenously three times a week for 6 months, then 18 units/kg three times a week for 6 months)
Trial: 1649718
Drug: Desferrioxamine chelation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine chelation therapy (30 mg/kg intravenously three times a week for 6 months)
Trial: 24149990
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream phonophoresis (2.5 % lidocaine, 2.5 % prilocaine)
Trial: 18674741
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (25 mg orally thrice a day for 3 months)
Trial: 10383539
Drug: Aqueous pump
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous pump spray 400 microg
Trial: 9345419
Drug: 9 MIU
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 MIU intramuscular recombinant interferon alpha‐2a (rIFNA) (Roferon‐A, Roche) (n = 12)
Trial: 9345419
Drug: rIFNA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFNA treatment
Trial: 24717258
Drug: VPA +
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA + memantine (5 mg/d)
Trial: 20598142
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of three medium hardboiled eggs
Trial: 20598142
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of egg substitute for 6 weeks
Trial: 12454298
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose prednisolone and continuous nebulised salbutamol (US regimen)
Trial: 12454298
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose prednisolone and bolus nebulised salbutamol (UK regimen)
Trial: 10511066
Drug: Ascending dosing
RxNorm normalized name: IODINE 1 kg in 1 kg TOPICAL LIQUID [ASCEND]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending dosing pattern of methylphenidate
Trial: 10511066
Drug: Twice-daily dosing
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily dosing pattern of methylphenidate
Trial: 10511066
Drug: Flat dosing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flat dosing pattern of methylphenidate
Trial: 8476617
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of 0.25% bupivacaine with epinephrine (0.5 mg per 100 ml of solution)
Trial: 8476617
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.5% bupivacaine with epinephrine (0.5 mg per 100 ml of solution)
Trial: 8476617
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (40 ml of 0.25% bupivacaine and 20 ml of 0.5% bupivacaine)
Trial: 3540875
Drug: Aspirin-caffeine-codeine-butalbital combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-caffeine-codeine-butalbital combination
Trial: 8867523
Drug: Acetaminophen-codeine combination
RxNorm normalized name: acetaminophen / codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen-codeine combination
Trial: 30337315
Drug: Aussie-FIT intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aussie-FIT intervention (12 weekly 90 min workshops)
Trial: 26081224
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA capsules
Trial: 26081224
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Dietary fish and n-3 PUFA capsules)
Trial: 24194642
Drug: Risperidone long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone long-acting injection (LAI) plus COMPASS (COMprehensive Psycho‐educational Approach and Scheme Set)
Trial: 24194642
Drug: Risperidone long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone long-acting injection (LAI) alone (control group)
Trial: 21448219
Drug: Probiotic milk
RxNorm normalized name: PROBIOTIC
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic milk drink (Yacult) consumed daily for 28 days
Trial: 12627043
Drug: Transdermal estradiol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol, 0.1 mg/day for 3 days
Trial: 9987969
Drug: psychotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: psychotherapy with biofeedback + hypotensive drugs
Trial: 9987969
Drug: hypotensive drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypotensive drugs only
Trial: 3042011
Drug: recombinant alpha‐interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant alpha‐interferon (rIFN‐alpha 2a2) in combination with etretinate
Trial: 3042011
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (rIFN-alpha 2a2 + etretinate)
Trial: 29141055
Drug: 1,064 nm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,064 nm laser treatment (5 monthly treatments)
Trial: 29141055
Drug: 532 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 532 nm laser treatment (4 monthly treatments)
Trial: 18248658
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg amitriptyline daily